human
cytomegaloviru
hcmv
infect
major
caus
morbid
recipi
organ
transplant
congenit
infect
infant
hcmv
vaccin
emerg
effect
approach
prevent
hcmv
infect
particularli
develop
multipl
viral
antigen
vaccin
human
leukocyt
antigen
hla
restrict
polyepitop
technolog
chines
popul
make
one
fifth
popul
worldwid
import
develop
hcmv
vaccin
specif
chines
popul
target
chineserestrict
hla
allel
antigen
present
studi
design
novel
chimer
polyepitop
vaccin
base
replicationdefici
adenoviru
encod
hcmv
cell
epitop
differ
hcmv
antigen
restrict
hla
hla
ii
allel
cover
chines
popul
result
show
recombin
adenoviru
vaccin
effici
transfect
express
peripher
blood
mononuclear
cell
pbmc
littl
cytopath
activ
also
endogen
process
present
pbmc
hcmvspecif
cytotox
lymphocyt
ctl
show
strong
cytolyt
activ
hcmv
polyepitopesensit
target
cell
ctl
activ
accompani
high
level
ifnc
product
stimul
specif
vigor
respons
recombin
adenoviru
vaccin
vitro
make
potenti
candid
use
transplant
recipi
congenit
infect
infant
human
cytomegaloviru
hcmv
found
univers
throughout
geograph
locat
socioeconom
group
seropreval
rang
hcmv
caus
clinic
diseas
fetu
neonat
immunocompromis
individu
transplant
recipi
hivinfect
patient
congenit
hcmv
infect
import
caus
hear
cognit
motor
impair
newborn
dollard
et
al
hyde
et
al
allograft
recipi
virem
dissemin
caus
endorgan
diseas
hepat
pneumon
gastroenter
retin
predispos
transplant
reject
develop
vaccin
two
popul
rate
high
prioriti
recent
two
hcmv
phase
clinic
trial
complet
posit
result
induct
humor
immun
show
hcmv
glycoprotein
b
gb
vaccin
potenti
decreas
incid
case
matern
congenit
cmv
infect
griffith
et
al
pass
et
al
also
gener
vaccin
express
conserv
conform
epitop
gb
protein
zhao
et
al
moreov
cellular
immun
provid
lymphocyt
shown
play
key
role
resolv
primari
infect
provid
longterm
immun
surveil
clearanc
replic
viru
crough
et
al
fornara
et
al
nebbia
et
al
therefor
great
import
develop
effect
hcmv
vaccin
base
viral
antigen
activ
cellular
immun
prevent
hcmvassoci
diseas
bund
et
al
einsel
et
al
past
year
variou
strategi
cellular
immun
includ
use
subunit
vaccin
dna
dens
bodi
vaccin
develop
promis
result
preclin
studi
demonstr
khanna
diamond
plotkin
schleiss
schleiss
strategi
hinder
limit
rang
epitop
hla
allel
could
includ
develop
hcmv
vaccin
ideal
formul
cover
viral
antigen
could
induc
broad
repertoir
hcmvspecif
cellular
immun
respons
recent
develop
polyepitop
technolog
allow
present
multipl
hla
class
irestrict
ctl
cytotox
lymphocyt
epitop
deriv
differ
antigen
within
singl
read
frame
thu
provid
new
platform
achiev
goal
epitopebas
vaccin
also
contain
minim
number
epitop
cover
vast
major
human
popul
buteau
et
al
fischer
et
al
khan
et
al
tcell
epitop
bind
multipl
allel
hla
prime
target
vaccin
immunotherapi
develop
due
relev
larg
proport
human
popul
exampl
sar
coronaviru
nucleocapsid
gupta
et
al
protein
berzofski
et
al
brown
et
al
surman
et
al
chlamydia
trachomati
outer
membran
protein
kim
demar
epitopebas
vaccin
effect
induc
cellular
immun
select
small
number
hotspot
elicit
requir
tcell
function
date
mani
studi
focus
hlarestrict
hcmv
epitop
vaccin
progress
made
elkington
et
al
rist
et
al
howev
investig
mainli
aim
caucasian
popul
gener
popul
limit
coverag
hla
allel
antigen
sinc
chines
popul
differ
ethnic
group
make
one
fifth
world
popul
essenti
develop
hcmv
epitop
vaccin
specif
chines
popul
target
chineserestrict
hla
allel
broader
antigen
develop
hcmv
vaccin
specif
chines
popul
design
novel
chimer
polyepitop
vaccin
base
replicationdefici
adenoviru
evalu
immunolog
effect
vitro
predict
select
chines
hlarestrict
hcmv
polyepitop
perform
accord
forecast
system
previous
publish
spatial
coverag
cumul
phenotyp
frequenc
cpf
hlai
xue
et
al
b
cpf
algorithm
allow
identif
allel
repres
desir
percentag
popul
also
allow
predict
theoret
respond
statu
given
popul
hla
gene
frequenc
known
briefli
cpf
hla
allel
site
chines
popul
forecast
immunoact
hlarestrict
hcmv
polyepitop
nucleotid
vaccin
differ
geograph
locat
evalu
util
literatur
data
hlarestrict
hcmv
epitop
publish
select
ctl
epitop
th
epitop
deriv
differ
hcmv
protein
antigen
induc
cellular
immunolog
respons
stabli
bind
correspond
class
class
ii
hla
molecul
syfpeithi
rammense
et
al
combin
mappp
algorithm
hakenberg
et
al
select
fig
schemat
view
construct
recombin
adenoviru
express
synthet
dna
encod
polyepitop
protein
contain
hcmv
tcell
epitop
dna
sequenc
encod
polyepitop
protein
synthes
use
overlap
epitop
sequenc
specif
primer
describ
section
synthet
insert
clone
plasmid
prior
clone
vector
amplif
e
coli
express
cassett
excis
ligat
express
vector
follow
linear
dna
use
pac
restrict
enzym
recombin
vector
packag
infecti
adenoviru
transfect
hek
cell
recombin
adenoviru
refer
harvest
transfect
cell
repeat
freezethaw
cycl
epitop
polyepitop
predict
specif
hlabind
valu
proteasom
cleavag
site
design
construct
recombin
adenoviru
vaccin
express
polyepitop
hcmv
shown
fig
amino
acid
sequenc
hla
restrict
epitop
translat
nucleotid
sequenc
use
human
univers
codon
usag
polyepitop
dna
sequenc
repres
epitop
synthes
use
splice
overlap
extens
stepwis
asymmetr
polymeras
chain
reaction
pcr
thomson
et
al
final
dna
sequenc
code
kozak
sequenc
start
codon
contigu
minim
hcmv
epitop
tabl
hexahistidin
tag
clone
vector
sequenc
sequenc
insert
shuttl
plasmid
kindli
provid
hiroyuki
mizuguchi
osaka
univers
osaka
japan
express
cassett
clone
vector
provid
hiroyuki
mizuguchi
verifi
restrict
digest
sequenc
recombin
linear
transfect
human
embryon
kidney
hek
cell
day
maxim
cytopath
effect
cpe
observ
includ
vector
control
recombin
adenovirus
harvest
transfect
cell
success
freezethaw
cycl
titer
largescal
viru
prepar
measur
plaqu
assay
confirm
success
develop
recombin
adenoviru
pcr
use
amplifi
dna
extract
virion
revers
transcript
rt
pcr
western
blot
use
confirm
mrna
protein
express
cell
parent
cell
serv
neg
control
pbmc
healthi
donor
cultur
plate
infect
h
day
postinfect
express
analyz
immunocytochemistri
follow
briefli
pbmc
place
slide
fix
paraformaldehyd
nonspecif
antibodi
site
block
goat
serum
cell
incub
tag
antibodi
abcam
cambridg
england
relev
isotyp
control
antibodi
overnight
slide
wash
pb
incub
hrpconjug
secondari
antibodi
slide
process
streptavidinperoxidas
sp
method
zhongshan
co
ltd
beij
china
min
follow
stain
diaminobenzidon
slide
visual
use
microscop
observ
express
local
recombin
polyepitop
proteasom
cleav
epitop
viabil
infect
pbmc
determin
trypan
blue
stain
epstein
barr
virustransform
lymphoblastoid
cell
line
lcl
establish
hcmvseroposit
donor
exogen
viru
transform
peripher
b
cell
use
viru
isol
autolog
lcl
puls
hcmv
peptid
use
stimul
cell
line
clone
weekli
basi
target
cell
cytotox
assay
see
cell
line
except
routin
maintain
medium
supplement
unitsml
penicillin
g
sodium
lg
ml
streptomycin
mmoll
lglutamin
fc
cell
line
maintain
dmem
contain
fc
hcmv
experiment
strain
cultur
fibroblast
peptid
synthes
merrifield
solid
phase
method
purchas
shanghai
sangon
biolog
engin
compani
dissolv
dimethyl
sulphoxid
dilut
serumfre
medium
puriti
peptid
examin
hplc
proven
peripher
blood
collect
donor
dna
extract
test
hla
allel
pcrssp
sequencespecif
primer
serum
use
detect
hcmv
statu
elisa
inform
consent
obtain
donor
ethic
approv
studi
obtain
ethic
committe
qilu
hospit
shandong
univers
polyclon
ctl
line
specif
hcmv
epitop
establish
accord
method
previous
publish
elkington
et
al
khanna
briefli
pbmc
healthi
viru
carrier
cocultur
autolog
xirradi
pbmc
puls
lmoll
peptid
h
day
growth
medium
ad
cell
expand
day
cultur
restimul
peptidesensit
xirradi
autolog
lcl
day
cultur
medium
cell
use
polyclon
effector
vitro
cytotox
assay
peptidesensit
autolog
lcl
hcmv
specif
ctl
gener
healthi
viru
carrier
stimul
pbmc
adenoviru
polyepitop
stimul
pbmc
healthi
viru
carrier
cocultur
autolog
xirradi
pbmc
infect
moi
respond
stimul
ratio
day
cultur
supplement
growth
medium
contain
day
cultur
restimul
adenovirusinfect
moi
xirradi
autolog
lcl
supplement
growth
medium
contain
hcmvspecif
tcell
reactiv
stimul
twice
sequenti
assess
day
use
vitro
cytotox
assay
ifnc
product
ldh
method
use
detect
cytotox
hcmvspecif
ctl
briefli
effector
cell
e
target
cell
seed
plate
differ
e
ratio
h
incub
cellfre
supernat
transfer
new
plate
reagent
ad
well
thirti
minut
later
ldh
releas
detect
spectrophotomet
nm
maxim
spontan
ldh
releas
obtain
ad
triton
complet
medium
target
cell
respect
percentag
specif
lysi
calcul
follow
formula
specif
lysi
sampl
releas
spontan
releas
maximum
releas
spontan
releas
pbmc
stimul
moi
ctl
restimul
moi
detect
elispot
measur
product
ifnc
accord
protocol
r
minneapoli
mn
cytokineproduc
cell
detect
purpl
spot
develop
micropl
analyz
count
spot
use
special
elispot
reader
quantit
result
done
calcul
number
spot
form
cell
sfc
per
number
cell
ad
well
cell
precursor
frequenc
epitop
base
total
number
cell
number
sfc
per
well
averag
triplic
well
spot
calcul
subtract
number
spot
neg
control
well
predomin
chineserestrict
allel
put
algorithm
cpf
cpf
set
allel
chines
popul
fig
allel
ad
algorithm
total
cpf
hla
allel
reach
chines
popul
fig
base
select
set
hla
allel
select
ctl
epitop
th
epitop
differ
hcmv
antigen
could
induc
widecoverag
immun
respons
stabli
bind
class
class
ii
hla
molecul
select
epitop
put
syfpeithi
algorithm
predict
score
select
epitop
reach
indic
high
hlabind
affin
mappp
could
predict
proteasom
cleavag
peptid
anchor
hla
molecul
select
polyepitop
sequenc
put
mappp
algorithm
predict
proteasom
cleavag
valu
reach
score
suggest
high
possibl
singl
epitop
product
present
tabl
epitop
includ
polyepitop
deriv
differ
viral
protein
gh
gb
involv
viru
attach
replic
assembl
reactiv
immun
escap
latent
phase
crucial
stage
progress
hcmv
infect
fulllength
nucleotid
sequenc
synthes
sequenc
clone
doubl
digest
nheinoti
iceuipiscei
produc
expect
fragment
confirm
construct
bp
express
cassett
clone
vector
produc
doubledigest
iceuipiscei
produc
two
expect
fragment
digest
xhoi
also
gener
seven
expect
fragment
fig
b
correct
insert
gene
confirm
sequenc
recombin
vector
control
packag
cell
emerg
recombin
adenovirus
cultiv
case
normal
cpe
observ
compar
uninfect
cell
green
fluoresc
observ
cell
indic
effici
transfect
gene
express
fig
recombin
adenoviru
harvest
transfect
cell
titer
measur
pfu
success
pcr
amplif
recombin
virion
dna
confirm
inclus
sequenc
recombin
adenoviru
virion
express
analyz
rtpcr
amplifi
fragment
expect
fig
protein
express
analyz
western
blot
use
antibodi
direct
tag
band
kda
correspond
predict
size
recombin
protein
observ
extract
cell
parent
cell
cell
fig
strong
express
antigen
found
pbmc
cell
infect
express
detect
pbmc
infect
control
typic
pattern
stain
indic
recombin
polyepitop
proteasom
cleav
epitop
might
local
cell
membran
cytoplasm
fig
express
timedepend
strongest
express
observ
day
signific
cytopath
activ
detect
infect
cell
cell
viabil
significantli
affect
infect
cell
remain
viabl
either
control
adenoviru
refer
h
expos
hcmvspecif
ctl
line
lcl
infect
adenoviru
vector
use
target
nlv
vle
vte
gpi
specif
ctl
line
e
ratio
use
assay
hcmvspecif
ctl
line
gener
healthi
viru
carrier
specif
confirm
abil
lyse
hlamatch
target
cell
coat
respect
epitop
fig
hlamatch
lcl
infect
moi
also
effici
recogn
individu
hcmvspecif
ctl
line
wherea
target
cell
infect
control
recogn
fig
cocultur
autolog
pbmc
infect
moi
respond
stimul
ratio
day
cultur
restimul
infect
moi
xirradi
autolog
lcl
growth
medium
supplement
uml
epitopespecif
cell
reactiv
subsequ
assess
day
use
vitro
cytotox
assay
autolog
lcl
coat
individu
peptid
epitop
lgml
uncoat
use
target
assay
e
ratio
activ
hcmvspecif
ctl
stimul
show
strong
cytolyt
activ
pbmc
healthi
viru
carrier
stimul
autolog
pbmc
infect
show
singl
stimul
highli
effici
rapidli
expand
cell
cell
exhibit
strong
hcmv
epitopespecif
cytolyt
activ
ctl
expand
two
differ
donor
show
reactiv
one
epitop
deriv
differ
antigen
exampl
cell
cultur
donor
jxx
show
strong
cytolyt
activ
epitop
come
two
antigen
donor
znn
demonstr
cytolyt
activ
epitop
come
antigen
fig
moreov
two
differ
moi
show
compar
level
cell
stimul
efficaci
also
confirm
test
expand
cell
popul
differ
effector
target
e
ratio
highli
effici
stimul
multipl
ctl
respons
strong
cytolyt
activ
four
differ
epitop
vte
hla
nlv
vle
hla
gpi
hla
observ
e
ratio
low
fig
c
moreov
cytolyt
activ
also
elev
increas
e
ratio
pbmc
stimul
produc
higher
ifnc
amount
control
effici
sensibil
pbmc
antigenspecif
ctl
addit
two
differ
moi
show
compar
level
ifnc
product
higher
ifnc
product
observ
moi
moi
especi
donor
jxx
fig
furthermor
ifnc
product
cell
pbmc
stimul
stimul
lower
ctl
restimul
stimul
twice
indic
stronger
hcmv
epitopespecif
cytolyt
activ
upon
twofold
stimul
fig
hcmv
diseas
remain
major
obstacl
allogen
bmt
prevent
hcmv
infect
vaccin
becam
highprior
goal
schleiss
adopt
transfer
hcmvspecif
ctl
cell
transplant
recipi
demonstr
therapeut
benefit
relat
hcmv
diseas
hebart
einsel
pegg
et
al
vaccin
induc
broad
repertoir
hcmvspecif
immun
respons
differ
ethnic
popul
variou
hla
allel
like
provid
effect
protect
hcmvassoci
pathogenesi
sinc
chines
popul
constitut
approxim
one
fifth
world
popul
extrem
polymorph
hla
allel
essenti
develop
hcmv
epitop
vaccin
specif
chines
prevent
worldwid
hcmv
infect
context
base
forecast
system
identifi
combin
hla
allel
site
cpf
hla
allel
site
chines
popul
reach
accord
select
hla
literatur
data
hlarestrict
hcmv
epitop
design
novel
chimer
vaccin
encod
hcmv
ctl
epitop
th
epitop
polyepitop
optim
select
epitop
precis
direct
evok
immun
respons
conserv
highli
immunogen
region
sever
antigen
therefor
addit
coverag
hla
allel
given
popul
good
epitopebas
vaccin
also
take
account
coverag
epitop
coverag
hlaantigen
combin
probabl
epitop
properli
cleav
sequenc
hcmv
open
read
frame
orf
accumul
evid
shown
hcmv
specif
immun
respons
restrict
gb
antigen
also
direct
toward
hcmv
read
frame
elkington
et
al
manley
et
al
schleiss
sylwest
et
al
includ
nonessenti
gene
encod
modul
adapt
immun
respons
studi
comput
method
cpf
algorithm
syfpeithi
algorithm
mappp
algorithm
predict
well
experiment
determin
epitop
incorpor
select
optim
polyepitop
epitop
includ
polyepitop
deriv
differ
viral
protein
involv
differ
stage
viral
infect
significantli
reduc
potenti
threat
immun
escap
select
express
antigen
describ
vaccin
incorpor
variou
antigen
express
reproduct
phase
viru
would
provid
strategi
immun
hcmv
infect
clinic
circumv
allel
specif
requir
th
epitop
seri
th
sequenc
promiscu
bind
hla
ii
allel
evalu
combin
polyepitop
studi
hcmv
epitop
encod
polyepitop
endogen
express
process
human
cell
found
stimul
rapidli
expand
multipl
antigenspecif
human
ctl
cell
healthi
viru
carrier
vitro
ctl
cell
exhibit
strong
hcmv
epitopespecif
cytolyt
activ
hla
restrict
target
cell
ifncproduc
cell
larg
induc
pbmc
stimul
expand
antigenspecif
ctl
indic
cell
reactiv
data
present
emphas
strength
adapt
polyepitopebas
approach
clinic
translat
may
lead
signific
advanc
applic
adopt
immunotherapi
wide
rang
diseas
use
hcmv
vaccin
develop
bmt
patient
develop
new
hcmv
vaccin
import
vaccin
high
immunogen
low
product
cost
low
pathogen
compar
tradit
adenovir
vector
use
studi
increasingli
recogn
high
effici
low
toxic
use
multipl
human
gene
therapi
clinic
trial
vector
contain
chimer
fiber
gene
encod
fiber
tail
combin
fiber
shaft
knob
domain
cell
entri
thought
mediat
receptor
express
human
cell
gaggar
et
al
liver
tropism
hepatox
significantli
lower
xin
et
al
importantli
infect
induc
acut
respons
product
proinflammatori
cytokin
use
vaccin
deliveri
vehicl
infecti
diseas
model
includ
hepat
c
thammanichanond
et
al
hiv
xin
et
al
potent
transgen
productspecif
antibodi
tcell
respons
report
term
efficaci
appear
effect
compar
vector
recombin
protein
express
hematopoiet
cell
yotnda
et
al
studi
success
construct
novel
hcmv
vaccin
base
replicationdefici
encod
hlaspecif
hcmv
polyepitop
nucleotid
vaccin
ex
vivo
infect
pbmc
consist
demonstr
high
express
polyepitop
antigen
low
toxic
turn
result
strong
stimul
antigen
specif
ctl
thu
combin
express
system
polyepitop
technolog
provid
potenti
strategi
expans
cell
summari
develop
recombin
adenoviru
vaccin
hcmv
base
express
system
polyepitop
technolog
cover
chines
popul
stimul
adenoviru
vector
express
hcmv
polyepitop
capabl
induc
multipl
independ
hlarestrict
ctl
respons
therefor
vaccin
may
promis
candid
clinic
trial
primeboost
strategi
combin
hcmv
vaccin
formul
might
also
use
approach
develop
suitabl
vaccin
nonchines
popul
conflict
interest
author
